Presentations
Publications

Scientific Presentations

date

document

Scientific Publications

  • Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer, an NCCN phase II Trial

    Authors: Mathew. Cowan, Wendy M. Swetzig, Valery Adorno-Cruz, Mario J. Pineda, Nikki L. Neubauer, Emily Berry, John R . Lurain, Shohreh Shahabi, Deanna Taiym, Valerie Nelson, Kaitlyn Lucrezi O’Shea, Masha Kocherginsky, Daniela Matei Click here for link to article.

  • Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis

    Authors: Victoria E. Wang, Bradley W. Blaser, Ravi K. Patel, Gregory K. Behbehani, Arjun A. Rao, Blythe Durbin-Johnson, Tommy Jiang, Aaron C. Logan, Matthew Settles, Gabriel N. Mannis, Rebecca Olin, Lloyd E. Damon, Thomas G. Martin, Peter H. Sayre, Karin M. Gaensler, Emma McMahon, Michael Flanders, Vivian Weinberg, Chun J. Ye, David P. Carbone, Pamela N. Munster, Gabriela K. Fragiadakis, Frank McCormick and Charalambos Andreadis Click here for link to article.

  • TiNivo: Safety and Efficacy of Tivozanib-Nivolumab Combination Therapy in Patients With Metastatic Renal Cell Carcinoma

    Authors: L. Albiges, P. Barthélémy, M. Gross-Goupil, S. Negrier, M.N. Needle, B. Escudier Click here for link to article.

  • Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma

    Authors: Sumanta K. Pal, Bernard J. Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, Daniel Powers, David F. McDermott, Brian I. Rini Click here for link to article.

  • A Multicentre Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer

    Authors: Julie E. Bauman, James Ohr, William E. Gooding, Robert L. Ferris, Umamaheswar Duvvuri, Seungwon Kim, Jonas T. Johnson, Adam C. Soloff, Gerald Wallweber, John Winslow, Autumn Gaither-Davis, Jennifer R. Grandis, Laura P. Stabile Click here for link to article.

  • A Multicentre Phase 1b/2 Study of Tivozanib in Patients With Advanced Inoperable Hepatocellular Carcinoma

    Authors: Christos Fountzilas, Medhavi Gupta, Sunyoung Lee, Smitha Krishnamurthi, Bassam Estfan, Katy Wang, Kristopher Attwood, John Wilton, Robert Bies, Wiam Bshara, Renuka Iyer  Click here for link to article.

  • Real-World Results from One Year of Therapy with Tivozanib

    Authors: Michael Staehler, Annabel K. Spek, Severin Rodler, Melanie Schott, Jozefina Casuscelli, Lena Mittelmeier and Marcus Schlemmer Click here for link to article.

  • Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma (TIVO-3): A Phase 3, Multicentre, Randomised, Controlled, Open-Label Study

    Authors: Brian I. Rini, Sumanta K. Pal, Bernard J. Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, David F. McDermott Request for Reprint of The Lancet Oncology TIVO-3 Manuscript.

  • Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial

    Authors: Robert J. Motzer, Dmitry Nosov, Timothy Eisen, Igor Bondarenko, Vladimir Lesovoy, Oleg Lipatov, Piotr Tomczak, Oleksiy Lyulko, Anna Alyasova, Mihai Harza, Mikhail Kogan, Boris Y. Alekseev, Cora N. Sternberg, Cezary Szczylik, David Cella, Cristina Ivanescu, Andrew Krivoshik, Andrew Strahs, Brooke Esteves, Anna erkenblit, Thomas E. Hutson Click here for link to article.

  • Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study

    Authors: Ana M. Molina a, Thomas E. Hutson b, Dmitry Nosov c, Piotr Tomczak d, Oleg Lipatov e, Cora N. Sternberg f, Robert Motzer g, Tim Eisen h Click here for link to article.

  • Tan – Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Gth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

    Authors: Eng-Huat Tan, Wan-Teck Lim, Myung-Ju Ahn, Quan-Sing Ng, Jin Seok Ahn, Daniel Shao-Weng Tan, Jong-Mu Sun, MayHan, Francis C. Payumo, Krista McKee, Wei Yin, Marc Credi, Shefali Agarwal, Jaroslaw Jac, and Keunchil Park Click here for link to article.

  • Mok – Ph2 Combo Fic and Gefitinib in Asian Pts with Pulmonary Adenocarcinoma

    Authors: Tony Shu Kam Mok, MD’Correspondence information about the author MD Tony Shu Kam MokEmail the author MD Tony Shu Kam Mok, Sarayut Lucien Geater, MD, Wu-Chou Su, MD, Eng-Huat Tan, M.B.B.S., James Chi-Hsin Yang, MD, PhD, Gee-Chen Chang, MD, May Han, PhD, Philip Komarnitsky, MD, PhD, MBA, Francis Payumo, ScM, Jennifer E. Garrus, PhD, Sandra Close, PhD, Keunchil Park, MD, PhD Click here for link to article.

  • Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic onization

    Authors: Shigetsugu Takano,1,2,3,4 Maximilian Reichert,1,2,3,5 Basil Bakir,1,2,3 Koushik K. Das,1,2,3 Takahiro Nishida,4 Masaru Miyazaki,4 Steffen Heeg,1,2,3,6 Meredith A. lins,1,2,3 Benoît Marchand,1,2,3 Philip D. Hicks,1,2,3 Anirban Maitra,7,8 and Anil K. Rustgi1,2,3,9. Click here for link to article. Click here for link to Supplemental Text and Figures.

  • Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma

    Authors: Nosov D, Esteves B, Lipatov O, Lyulko A, Anischenko A, Chacko R, Doval D, Strahs A, Slichenmyer W, and Bhargava P JCO May 10, 2012:1678-1685; DOI:10.1200/JCO.2011.35.3524. Click here for link to article.

  • Biological and Clinical Activity of Tivozanib, a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4 Week on, 2 Week off Schedule in Patients With Advanced Solid Tumors.

    Authors: Eskens FALM, de Jonge MJA, Bhargava P, Isoe T, Cotreau MM, Esteves B, Hayashi K, Burger H, Thomeer M, van Doorn L, Verweij J. Clin Cancer Res. 10.1158/1078-0432.CCR-11-0411. (October 5, 2011). Click here for link to article.

  • Development of second-generation VEGFR tyrosine kinase inhibitors: Current status

    Authors: Bhargava P, Robinson MO. Curr On Rep. 2011. doi:10.1007/s11912-011-0154-3. Click here for link to article.

  • GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling

    Authors: Bai A, Meetze K, Vo NY, Kollipara S, Mazsa EK, Winston WM, Weiler S, Poling LL, Chen T, Ismail NS, Jiang J, Lerner L, Gyuris J, Weng Z. Cancer Res. 2010 Oct 1;70(19):7630-9. Epub 2010 Aug 13. Click here for link to article.

  • Non-germline genetically engineered mouse models for translational cancer research

    Authors: Joerg Heyer, Lawrence N. Kwong, Scott W. Lowe and Lynda Chin Nature Reviews Cancer, July 2010, vol. 10, no. 7, 470-80. Click here for article.

  • Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.

    Authors: Yinghui Zhou, William M. Rideout 3rd, Tong Zi, Angela Bressel, Shialaja Reddypalli, Rebecca Rancourt, Jin K. Woo, James W. Horner, Lynda Chin, M. Isabel Chiu, Marcus Bosenberg, Tyler Jacks, Steven C. Clark, Ronald A. Depinho, Murray O. Robinson, and Joerg Heyer. Nat Biotechnol. 2010 Jan;28(1):71-8. Epub 2009 Dec 20

  • Cancer Drug Discovery and Development: The Oncogenomics Handbook

    Edited by W. J. LaRochelle and R. A. Shimkets © Humana Press Inc., April 2005.

  • Genetically Engineered Mouse Models of Human Cancer for Drug Discovery and Development (Chapter 16)

    Authors: Ronan C. O’Hagan, Min Wu, William M. Rideout III, Yinghui Zhou and Joerg Heyer

  • Essential role for oncogenic Ras in tumour maintenance

    Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O’Hagan R, Pantginis J, Zhou H, Horner JW 2nd, Cordon-Cardo C, Yancopoulos GD, DePinho RA. Nature. 1999 Jul 29; 400(6743): 468-72.

The listed publications and presentations discuss investigational new drugs that have not been approved by the U.S. Food and Drug Administration.